Elekta AB (EKTAY)
8.12
+0.02
(+0.25%)
USD |
OTCM |
May 31, 16:00
Elekta Enterprise Value: 3.440B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 3.440B |
| May 30, 2024 | 3.432B |
| May 29, 2024 | 3.413B |
| May 28, 2024 | 3.480B |
| May 24, 2024 | 3.404B |
| May 23, 2024 | 3.398B |
| May 22, 2024 | 3.403B |
| May 21, 2024 | 3.345B |
| May 20, 2024 | 3.299B |
| May 17, 2024 | 3.252B |
| May 16, 2024 | 3.268B |
| May 15, 2024 | 3.249B |
| May 14, 2024 | 3.209B |
| May 13, 2024 | 3.192B |
| May 10, 2024 | 3.152B |
| May 09, 2024 | 3.071B |
| May 08, 2024 | 3.106B |
| May 07, 2024 | 3.110B |
| May 06, 2024 | 3.115B |
| May 03, 2024 | 3.039B |
| May 02, 2024 | 3.022B |
| May 01, 2024 | 3.027B |
| April 30, 2024 | 3.092B |
| April 29, 2024 | 3.075B |
| April 26, 2024 | 2.957B |
| Date | Value |
|---|---|
| April 25, 2024 | 2.898B |
| April 24, 2024 | 2.982B |
| April 23, 2024 | 3.031B |
| April 22, 2024 | 2.987B |
| April 19, 2024 | 2.909B |
| April 18, 2024 | 2.926B |
| April 17, 2024 | 2.963B |
| April 16, 2024 | 3.001B |
| April 15, 2024 | 3.047B |
| April 12, 2024 | 3.020B |
| April 11, 2024 | 3.133B |
| April 10, 2024 | 3.165B |
| April 09, 2024 | 3.248B |
| April 08, 2024 | 3.325B |
| April 05, 2024 | 3.266B |
| April 04, 2024 | 3.295B |
| April 03, 2024 | 3.320B |
| April 02, 2024 | 3.265B |
| April 01, 2024 | 3.232B |
| March 28, 2024 | 3.207B |
| March 27, 2024 | 3.230B |
| March 26, 2024 | 3.228B |
| March 25, 2024 | 3.231B |
| March 22, 2024 | 3.215B |
| March 21, 2024 | 3.217B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.046B
Minimum
Sep 27 2022
6.004B
Maximum
Jun 07 2021
4.025B
Average
3.721B
Median
Enterprise Value Benchmarks
| Abliva AB | 10.57M |
| Karolinska Development AB | 62.17M |
| Calliditas Therapeutics AB | 1.090B |
| Oncopeptides AB | 12.46M |
| Olink Holding AB | 2.874B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 29.37M |
| Revenue (Quarterly) | 436.89M |
| Total Expenses (Quarterly) | 382.20M |
| EPS Diluted (Quarterly) | 0.077 |
| Gross Profit Margin (Quarterly) | 36.68% |
| Profit Margin (Quarterly) | 6.72% |
| Earnings Yield | 4.37% |
| Operating Earnings Yield | 7.54% |
| Normalized Earnings Yield | 4.374 |